Actuate Therapeutics (ACTU) Long-Term Debt Issuances (2024)
Actuate Therapeutics (ACTU) posted quarterly Long-Term Debt Issuances of $1.0 million for Q2 2024, down 77.78% quarter-over-quarter from $4.5 million in Q1 2024.
Actuate Therapeutics (ACTU) Long-Term Debt Issuances (2024) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Long-Term Debt Issuances for 1 consecutive years, with $1.0 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Long-Term Debt Issuances changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2025 stood at $1.0 million (changed N/A YoY), while the FY2024 annual figure was $5.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances retreated to $1.0 million in Q2 2024 per ACTU's latest filing, from $4.5 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $4.5 million in Q1 2024 and bottomed at $1.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 4.50 Mn |
| Mar 31, 2024 | 4.50 Mn |